BIOEQUIVALENCE STUDY OF 400 AND 100 MG IMATINIB FILM-COATED TABLETS IN HEALTHY VOLUNTEERS

• Authors: ANDRZEJ OSTROWICZ , PRZEMYSŁAW Ł. MIKOŁAJCZAK , MARZENA WIERZBICKA , PIOTR BOGURADZKI
• Languages of publication: EN

Abstracts

EN

The aim of the study was to investigate the bioavailability of a generic product of 100 mg and 400 mg imatinib film-coated tablets (test) as compared to that of a branded product (reference) at the same strength to determine bioequivalence. The secondary objective of the study was to evaluate tolerability of both products. An open-label, randomized, crossover, two-period, single-dose, comparative study was conducted in 43 (Imatynib-Biofarm 100 mg film-coated tablet) and in 42 (Imatynib-Biofarm 400 mg film-coated tablet), brand name Imatenil, Caucasian healthy volunteers in fed conditions. A single oral dose administration of the test or reference product was separated by 14-day washout period. The imatinib and its metabolite N-desmethyl imatinib concentrations were determined using a validated LC MS/MS method. The results of the single-dose study in healthy volunteers indicated that the film-coated tablets of Imatynib-Biofarm 100 mg and 400 mg film-coated tablets manufactured by Biofarm Sp. z o.o. (test products) are bioequivalent to those of Glivec 100 mg and 400 mg film-coated tablets manufactured by Novartis Pharma GmbH (reference products). Both products in the two doses of imatinib were well tolerated.

Keywords

EN

bioequivalence; imatinib; relative bioavailability; tolerability

Discipline

• PHARMACOLOGY: PHARMACOLOGY

• Journal: Acta Poloniae Pharmaceutica - Drug Research
• Year: 2014
• Volume: 71
• Issue: 5
• Pages: 843-854

Dates

published

2014

Contributors

author

ANDRZEJ OSTROWICZ

author

PRZEMYSŁAW Ł. MIKOŁAJCZAK

author

MARZENA WIERZBICKA

author

PIOTR BOGURADZKI

References

• 1. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B.: Nat. Med. 2, 561 (1996).
• 2. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B. et al.: N. Engl. J. Med. 344, 1031 (2001).
• 3. Buchdunger E., O'Reilly T., Wood J.: Eur. J.Cancer. 38, Suppl. 5, S28 (2002).
• 4. Druker B.J, Lydon N.B.: J. Clin. Invest. 105, 3 (2000).
• 5. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., Lydon N.B.: J. Pharmacol. Exp. Ther. 295, 139 (2000).
• 6. Mughal T.I., Goldman J.M.: Eur. J. Cancer 37, 561 (2000).
• 7. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., Cornelissen J.J. et al.: N. Engl. J. Med. 348, 994 (2003).
• 8. Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., Gathmann I. et al.: N. Engl. J. Med. 349, 1423 (2003).
• 9. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., Deininger M.W. et al.: N. Engl. J. Med. 355, 2408 (2006).
• 10. Lee H.J., Thompson J.E., Wang E.S., Wetzler M.: Cancer 117, 1583 (2011).
• 11. Mechtersheimer G., Egerer G., Hensel M., Rieker R.J., Libicher M., Lehnert T., Penzel R.: Virchows Arch. 444, 108 (2004).
• 12. Chabner B.A., Amrein P.C., Druker B.J., Michaelson M.D., Mitsiades C.S., Goss P.E., Ryan D.P. et al.: Chapter 62. Antineoplastic agents. in Goodman & Gilmanís The Pharmacological Basis of Therapeutics, 12th edn., McGraw-Hill, New York 2011.
• 13. Mac K., Wójcik M.: Postepy Hig. Med. Dosw. 62, 272 (2008).
• 14. Prenen H., Dumez H., Stefan C., Hoeben A., Wouters C., Van Lierde M.A., Sciot R. et al.: Acta Gastroenterol. Belg. 69, 367 (2006).
• 15. Nishida T., Shirao K., Sawaki A., Koseki M., Okamura T., Ohtsu A., Sugiyama T. et al.: Int. J. Clin. Oncol. 13, 244 (2008).
• 16. Chen P., Zong L., Zhao W., Shi L.: World J. Gastroenterol. 16, 4227 (2010).
• 17. Gronchi A., Blay J.Y., Trent J.C.: Cancer116(8), 1847 (2010).
• 18. Klion A.D., Robyn J., Maric I., Fu W., Schmid L., Lemery S., Noel P. et al.: Blood110, 3552 (2007).
• 19. Wang L.N., Pan Q., Fu J.F., Shi J.Y., Jin J., Li J.M., Hu J. et al.: Chin. Med. J. (Engl) 121, 867 (2008).
• 20. Intermesoli T., Delaini F., Acerboni S., Salmoiraghi S., Spinelli O., Guerini V., Vannucchi A.M. et al.: Br. J. Haematol. 147, 681 (2009).
• 21. Zhang Y., Qin T.J., Zhou C.L., Liu L., Xiao Z.J.: Zhonghua Xue Ye Xue Za Zhi 30, 381 (2009).
• 22. Peng B., Lloyd P., Schran H.: Clin. Pharmacokinet. 44, 879 (2005).
• 23. Gschwind H.P., Pfaar U., Waldmeier F., Zollinger M., Sayer C., Zbinden P., Hayes M. et al.: Drug Metab. Dispos. 33, 1503 (2005).
• 24. Peng B., Dutreix C., Mehring G., Hayes M.J., Ben-Am M., Seiberling M., Pokorny R. et al.: J. Clin. Pharmacol. 44, 158 (2004).
• 25. Fitos I., Visy J., Zsila F., Mady G., Simonyi M.: Biochim. Biophys. Acta. 1760, 1704 (2006).
• 26. Cross S.A., Lyseng-Williamson K.A.: Drugs67, 2645 (2007).
• 27. Gleevec - Rx List. The Internet Drug Index [data- base on the Internet]. WebMD, Inc. [last revised May2011; cited: 2013 April 26]. Available from: http:// www. rxlist.com/gleevec -drug. htm
• 28. The European Agency for the Evaluation of Medicinal Products, Note for Guidance on the Investigation of Bioavailability and Bioequivalence CPMP/EWP/QWP/1401/98, London, 26 July 2001.
• 29. The European Medicines Agency, Guidance on the Investigation of Bioequivalence CPMP/ EWP/QWP/1401/98 Rev.1, London, 20 January 2010.
• 30. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assambly, Helsinki June 1964 and amended by the 59th WMA General Assambly Seoul, Korea 2008.
• 31. European Agency for Evaluation of Medicinal Products, International Conference on Harmo- nization, in World Health Organization. Guideline for Good Clinical Practice, ICH topic E6. Geneva2002.
• 32. FDA Guidance for Industry. Statistical approaches to establishing bioequivalence. U.S. Food and Drug Administration, Rockville, MD2001.
• 33. Schuirmann D.J.: J. Pharmacokinet. Biopharm. 15, 657 (1987).
• 34. Nikolova Z., Peng B., Hubert M., Seiberling M., Keller U., Ho Y.-Y., Schran H., Capdeville R.: Cancer Chemother. Pharmacol. 53, 433 (2004).
• 35. Wilkinson G.R.: J. Pharmacokinet. Biopharm. 24, 475 (1996).
• 36. Grillo D., Polla G., VegaD.: J. Pharm. Sci. 101, 541 (2012).
• 37. Guidance for Industry. ANDAs: Pharmaceu- tical Solid Polymorphism. Chemistry, Manu- facturing, and Controls Information. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), July 2007, OGD, http://www.fda.gov/cder/guidance/index. htm
• 38. Szczepek W., Samson-Lazinska D., Zagrodzki B., Glice M., Maruszak W., Korczak K., Mo- dzelewski R. et al.: ìCrystalline methanesulfon- ic acid addition salts of imatinibî, WO2005/095379 A2 (2005).
• 39. Zimmermann J. et al.: Polish patent 188348 B1 (1998).

• Document Type: article